BRAF and intestinal cancer: In the next study, we will carry on to enlarge the sample size for a multicenter trial and collect patients’ gene statuses of MSI, RAS, BRAF, PIK3CA, and Her2 to analyze the relationship between mSEPT9 and common mutated genes of bowel cancer, and to establish a diagnostic model for the surveillance of bowel cancer postoperative recurrence, with the aim of providing more bases for the selection of individualized postoperative treatment.